(ZIMV) ZimVie - Ratings and Ratios
Dental Implants, Biomaterials, Digital Dentistry, Restorative Products, Surgical Kits
ZIMV EPS (Earnings per Share)
ZIMV Revenue
Description: ZIMV ZimVie
ZimVie Inc. is a dental technology company that develops, manufactures, and markets products and solutions for dental tooth replacement and restoration procedures globally. The companys product portfolio includes dental implant systems, biomaterials, digital dentistry solutions, and patient-specific restorative solutions.
Key products and services offered by ZimVie include bone grafts, barrier membranes, and collagen wound care products, as well as virtual treatment planning services and guided surgery solutions. The company sells its products to a diverse customer base, including oral surgeons, dental specialists, general dentists, and dental laboratories, through various channels such as sales representatives, independent sales agents, and distributors.
From a financial perspective, ZimVies market capitalization is approximately $251.29 million, with a forward price-to-earnings ratio of 11.14. The companys return on equity is currently negative, indicating a need for improvement in profitability. To evaluate the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating expense ratio can be monitored. Additionally, metrics like dental implant market share, customer satisfaction ratings, and product innovation pipeline can provide insights into the companys competitive position and future prospects.
Some relevant KPIs to track for ZimVie include: - Revenue growth rate: to assess the companys ability to expand its customer base and increase sales. - Gross margin: to evaluate the companys pricing power and production efficiency. - Research and development (R&D) expense as a percentage of revenue: to gauge the companys commitment to innovation and new product development. - Customer acquisition cost and customer retention rate: to assess the companys sales and marketing effectiveness. - Product mix and average selling price (ASP) trends: to understand the companys pricing strategy and product portfolio optimization.
Additional Sources for ZIMV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
ZIMV Stock Overview
Market Cap in USD | 251m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2022-03-01 |
ZIMV Stock Ratings
Growth Rating | -58.0 |
Fundamental | -18.4 |
Dividend Rating | 0.0 |
Rel. Strength | -48.5 |
Analysts | 3.25 of 5 |
Fair Price Momentum | 8.23 USD |
Fair Price DCF | 4.22 USD |
ZIMV Dividends
Currently no dividends paidZIMV Growth Ratios
Growth Correlation 3m | 10.6% |
Growth Correlation 12m | -95.3% |
Growth Correlation 5y | -15.2% |
CAGR 5y | -28.42% |
CAGR/Max DD 5y | -0.32 |
Sharpe Ratio 12m | -0.55 |
Alpha | -64.55 |
Beta | 0.913 |
Volatility | 69.44% |
Current Volume | 72.4k |
Average Volume 20d | 116.3k |
Stop Loss | 8.5 (-5.6%) |
As of July 13, 2025, the stock is trading at USD 9.00 with a total of 72,411 shares traded.
Over the past week, the price has changed by -4.56%, over one month by -5.56%, over three months by -1.64% and over the past year by -51.90%.
Neither. Based on ValueRay´s Fundamental Analyses, ZimVie is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -18.39 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ZIMV is around 8.23 USD . This means that ZIMV is currently overvalued and has a potential downside of -8.56%.
ZimVie has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold ZIMV.
- Strong Buy: 1
- Buy: 0
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to our own proprietary Forecast Model, ZIMV ZimVie will be worth about 9.2 in July 2026. The stock is currently trading at 9.00. This means that the stock has a potential upside of +2%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 11.7 | 29.7% |
Analysts Target Price | 11.7 | 29.7% |
ValueRay Target Price | 9.2 | 2% |